Sona Successfully Completes FDA-required Toxicity Study
Halifax, Nova Scotia – (Newsfile Corp. – May 27, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc.
Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, “This study indicates Sona’s gold nanorods were well tolerated, with no signs of acute or systemic toxicity at 100 times the proposed clinical dosage level. The tissue distribution profile was consistent with known nanoparticle pharmacokinetics. These results support the continued development for nanomedical applications in general and for Sona’s novel, developing cancer therapy, in particular.”
